Consensus Tarsus Pharmaceuticals, Inc.

Stocks

TARS

US87650L1035

Pharmaceuticals

Real-time Estimate Cboe BZX 15:59:53 2026-08-13 EDT			5-day change	1st Jan Change
68.86 ^USD	-1.65%		+4.61%	-16.54%

08-12	Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating	MT
08-07	Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating	MT

Evolution of the Average Target: Tarsus Pharmaceuticals, Inc.

Evolution of the Target Price: Tarsus Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Tarsus Pharmaceuticals, Inc.

fc469.ZPqjiq-0U3Q9xVp1gAswCDbu_Zy8glW5AlpMi4OKcXw.VYCX3uT4OAJ8vwAesVEGTH6LyPn2yyTeQ297vPblKCQyyO7b7tlkNmK_ag~53960c859e368bc072ee0323c15870ac

Analysts' recommendations: Tarsus Pharmaceuticals, Inc.

08-12	Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating	MT
08-07	Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating	MT
07-31	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating	MT
04-24	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $98 From $105, Maintains Outperform Rating	MT
04-23	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $100 From $101, Keeps Outperform Rating	MT
03-26	Mizuho Lifts Price Target on Tarsus Pharmaceuticals to $101 From $100, Keeps Outperform Rating	MT
02-25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating	MT
11-20	Mizuho Initiates Tarsus Pharmaceuticals at Outperform With $100 Price Target	MT
25-10-09	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
25-10-09	BofA Ups Price Target on Tarsus Pharmaceuticals to $85 From $80	MT
25-08-06	Tarsus Pharmaceuticals Q2 revenue beats expectations	RE
25-06-02	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating	MT
25-02-03	BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74	MT
25-01-22	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $72 From $65, Keeps Outperform Rating	MT
24-11-14	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	MT
24-08-09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating	MT
24-05-09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT
24-02-29	Goldman Sachs Adjusts Price Target on Tarsus Pharmaceuticals to $30 From $19, Maintains Neutral Rating	MT
24-02-28	Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating	MT
23-11-20	Goldman Sachs Starts Tarsus Pharmaceuticals With Neutral Rating, $19 Price Target	MT
23-11-10	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $42, Keeps Buy Rating	MT
23-09-11	Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $49 From $46, Maintains Buy Rating	MT
23-08-11	HC Wainwright Adjusts Tarsus Pharmaceuticals Price Target to $42 From $50, Maintains Buy Rating	MT
23-07-26	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $44, Maintains Buy Rating	MT
23-07-18	William Blair Initiates Tarsus Pharmaceuticals at Outperform Rating	MT